Cornerstone begins Phase II trial of lung cancer drug
US-based Cornerstone Pharmaceuticals has started a Phase II clinical trial of its lead Altered Energy Metabolism Directed (AEMD) drug candidate, CPI-613 for the treatment of patients with relapsed or refractory small cell lung cancer (SCLC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Pharmaceuticals | Small Cell Lung Cancer